RU2013157860A - Производные бензотиазинтиона, способы их получения и применение - Google Patents
Производные бензотиазинтиона, способы их получения и применение Download PDFInfo
- Publication number
- RU2013157860A RU2013157860A RU2013157860/04A RU2013157860A RU2013157860A RU 2013157860 A RU2013157860 A RU 2013157860A RU 2013157860/04 A RU2013157860/04 A RU 2013157860/04A RU 2013157860 A RU2013157860 A RU 2013157860A RU 2013157860 A RU2013157860 A RU 2013157860A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- substituted
- halogen
- independently represent
- substituent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 147
- 125000001424 substituent group Chemical group 0.000 claims abstract 49
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 38
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 36
- 229910052794 bromium Inorganic materials 0.000 claims abstract 35
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 35
- 229910052736 halogen Inorganic materials 0.000 claims abstract 31
- 150000002367 halogens Chemical class 0.000 claims abstract 30
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 23
- 125000004442 acylamino group Chemical group 0.000 claims abstract 18
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims abstract 18
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims abstract 18
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract 16
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 7
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 5
- 229910004013 NO 2 Inorganic materials 0.000 claims 54
- 125000000217 alkyl group Chemical group 0.000 claims 13
- -1 CF 3 Inorganic materials 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 239000003054 catalyst Substances 0.000 claims 2
- CLMOIKBPZOWYHA-UHFFFAOYSA-N 1,3-thiazine-4-thione Chemical compound S=C1C=CSC=N1 CLMOIKBPZOWYHA-UHFFFAOYSA-N 0.000 claims 1
- 150000003990 18-crown-6 derivatives Chemical group 0.000 claims 1
- DTIVHCYCOSCMFQ-UHFFFAOYSA-N 2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-8-nitro-6-(trifluoromethyl)-1,3-benzothiazine-4-thione Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC(C(N=2)=S)=C1SC=2N(CC1)CCC21OCCO2 DTIVHCYCOSCMFQ-UHFFFAOYSA-N 0.000 claims 1
- IKXQTHITUQDCQS-UHFFFAOYSA-N 2-(ethylamino)-6,8-dinitro-1,3-benzothiazine-4-thione Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C2SC(NCC)=NC(=S)C2=C1 IKXQTHITUQDCQS-UHFFFAOYSA-N 0.000 claims 1
- MLEBZKMHZMISLZ-UHFFFAOYSA-N 2-(methylamino)-6,8-dinitro-1,3-benzothiazine-4-thione Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C2SC(NC)=NC(=S)C2=C1 MLEBZKMHZMISLZ-UHFFFAOYSA-N 0.000 claims 1
- HSFKIEGLVDOLIQ-UHFFFAOYSA-N 2-morpholin-4-yl-6,8-dinitro-1,3-benzothiazine-4-thione Chemical compound N=1C(=S)C2=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C2SC=1N1CCOCC1 HSFKIEGLVDOLIQ-UHFFFAOYSA-N 0.000 claims 1
- ZHIVBLVAMJDSLN-UHFFFAOYSA-N 2-morpholin-4-yl-8-nitro-6-(trifluoromethyl)-1,3-benzothiazine-4-thione Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC(C(N=2)=S)=C1SC=2N1CCOCC1 ZHIVBLVAMJDSLN-UHFFFAOYSA-N 0.000 claims 1
- PZJHZQMOEWSPBV-UHFFFAOYSA-N 6,8-dinitro-2-piperidin-1-yl-1,3-benzothiazine-4-thione Chemical compound N=1C(=S)C2=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C2SC=1N1CCCCC1 PZJHZQMOEWSPBV-UHFFFAOYSA-N 0.000 claims 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 claims 1
- 229940121383 antituberculosis agent Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 claims 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000000814 tuberculostatic agent Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- YLPBUMOJYDPQJB-UHFFFAOYSA-N CN(CC1)CCC11OCCO1 Chemical compound CN(CC1)CCC11OCCO1 YLPBUMOJYDPQJB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110139840.2 | 2011-05-27 | ||
| CN201110139840.2A CN102276598B (zh) | 2011-05-27 | 2011-05-27 | 苯并噻嗪硫酮衍生物及其制备方法和用途 |
| PCT/CN2011/075750 WO2012162912A1 (zh) | 2011-05-27 | 2011-06-15 | 苯并噻嗪硫酮衍生物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013157860A true RU2013157860A (ru) | 2015-07-10 |
Family
ID=45102383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013157860/04A RU2013157860A (ru) | 2011-05-27 | 2011-06-15 | Производные бензотиазинтиона, способы их получения и применение |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140303152A1 (https=) |
| EP (1) | EP2719691A1 (https=) |
| CN (1) | CN102276598B (https=) |
| IN (1) | IN2013MN02414A (https=) |
| RU (1) | RU2013157860A (https=) |
| WO (1) | WO2012162912A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103508980B (zh) * | 2012-06-14 | 2016-07-06 | 四川大学 | 苯并噻嗪-4-酮衍生物及其制备方法和用途 |
| US9572809B2 (en) | 2012-07-18 | 2017-02-21 | Spero Trinem, Inc. | Combination therapy to treat Mycobacterium diseases |
| CN104211708B (zh) * | 2013-05-29 | 2018-08-24 | 中国医学科学院药物研究所 | 苯并噁嗪酮衍生物及其作为抗菌剂的应用 |
| US9481683B2 (en) * | 2014-06-09 | 2016-11-01 | University Of Notre Dame Du Lac | 1,3-benzothiazinone sulfoxide and sulfone compounds |
| CN105294597B (zh) * | 2015-11-03 | 2017-11-24 | 华东师范大学 | 苯并噻嗪类衍生物及其合成方法和应用 |
| RU2752568C2 (ru) * | 2016-09-22 | 2021-07-29 | Ляйбниц-Институт Фюр Натурштофф-Форшунг Унд Инфекционсбиологи Е.Ф. Ханс-Кнёлль Институт (Хки) | Новые антимикробные соединения, их применение для лечения инфекций млекопитающих и новый метаболический механизм |
| CN108456204B (zh) * | 2017-02-17 | 2023-05-26 | 四川大学 | 苯并噻嗪衍生物及其制备方法和用途 |
| CN108947952B (zh) * | 2017-05-24 | 2021-09-21 | 中国医学科学院药物研究所 | 2-取代氨基-5-三氟甲基-8-硝基苯并（硫代）吡喃-4-酮类化合物及其制备方法和用途 |
| CN114957232B (zh) * | 2021-05-28 | 2023-06-30 | 四川大学 | 一种苯并二氢恶嗪类化合物及其制备方法和抗结核的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5068813B2 (ja) * | 2006-05-24 | 2012-11-07 | ライブニッツ インスティトゥート フォー ナチュラル プロダクト リサーチ アンド インフェクション バイオロジー エー．ファウ． ハンス−クネル−インスティトゥート（ハーカーイー） | 新規なベンゾチアジノン誘導体、及び抗菌剤としてのその使用 |
| EP2020406A1 (en) * | 2007-07-16 | 2009-02-04 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Hans-Knöll-Institut | New antimicrobial compounds, their synthesis and their use for treatment of mammalian infection |
-
2011
- 2011-05-27 CN CN201110139840.2A patent/CN102276598B/zh not_active Expired - Fee Related
- 2011-06-15 RU RU2013157860/04A patent/RU2013157860A/ru unknown
- 2011-06-15 US US14/234,501 patent/US20140303152A1/en not_active Abandoned
- 2011-06-15 IN IN2414MUN2013 patent/IN2013MN02414A/en unknown
- 2011-06-15 WO PCT/CN2011/075750 patent/WO2012162912A1/zh not_active Ceased
- 2011-06-15 EP EP11866737.7A patent/EP2719691A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN102276598B (zh) | 2014-11-05 |
| CN102276598A (zh) | 2011-12-14 |
| US20140303152A1 (en) | 2014-10-09 |
| EP2719691A1 (en) | 2014-04-16 |
| IN2013MN02414A (https=) | 2015-06-12 |
| WO2012162912A1 (zh) | 2012-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013157860A (ru) | Производные бензотиазинтиона, способы их получения и применение | |
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| ATE537169T1 (de) | Piperidin- und piperazinderivate als p2x3- antagonisten | |
| PE20081059A1 (es) | Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk) | |
| AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
| PE20071009A1 (es) | Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3 | |
| RU2009141982A (ru) | Пиримидиновые производные | |
| JP2010522713A5 (https=) | ||
| AR060046A1 (es) | Derivados de 2, 4-dioxo-1, 4-dihidropirido[2, 3 -d]pirimidina, un proceso para prepararlos e intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por pde4 | |
| CN109803967A (zh) | 二氢嘧啶类化合物及其制备方法和用途 | |
| RU2007139453A (ru) | Гетеробициклические ингибиторы вируса гепатита с (hcv) | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| PE20121127A1 (es) | Derivados de piridina y pirazina como moduladores de cinasa de proteina | |
| JP2009511490A5 (https=) | ||
| CO5690643A2 (es) | Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos | |
| PY1030698A (es) | Mezclas pesticidas mesoionicos | |
| WO2008005914A3 (en) | Novel glucokinase activators and methods of using same | |
| AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
| TW200637550A (en) | Thiazole-4-carboxamide derivatives as mGluR5 antagonists | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| TR201909709T4 (tr) | Fosfordiesteraz inhibitörleri olarak benzodioksol türevleri. | |
| CO6150182A2 (es) | Modulares de benzofuro y benzotienopirimidina del receptor h4 de histamina | |
| WO2008007123A3 (en) | Pharmaceutical compounds | |
| EA201170099A1 (ru) | Замещенные пиримидин-4-оновые производные | |
| EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии |